SPIEF 2025: AIPM presents at "Neoethics in the Age of Neurotechnology"

Elena Popova, Senior Director of Regulatory Affairs & Healthcare at AIPM, outlined the key areas of focus for the pharmaceutical industry in neuroscience and the regulatory hurdles posed by emerging technologies.

During the Russian Pharmaceutical Forum on Drug Safety, held as part of the St. Petersburg International Economic Forum, experts delved into the regulation and ethics of neurotechnology.

Mikhail Murashko, Minister of Health of the Russian Federation, Hans Henrik P. Kluge, Director of the WHO Regional Office for Europe, and Alexander Alimov, Executive Secretary of the Russian Federation Commission for UNESCO, joined leading Russian experts, including neurotechnology developers, at the session "Neophilosophy in the Age of Neurotechnology."

Elena Popova presented the pharmaceutical industry's view, outlining the main areas of work and regulatory challenges:
● Over the past five years, the pharmaceutical industry has significantly increased investments in drug development, particularly for neurodegenerative diseases and dementia
● Digital transformation and artificial intelligence have spurred a technological revolution
● The creation of combination products and remote monitoring is enabling personalized and holistic treatment approaches
● There's a significant gap between technological advancements and regulatory adaptability
● The introduction of new methods, including AI, requires substantial updates to the regulatory system, including interdisciplinary centers of competence, regulatory consortia, and sandboxes
● Protecting personal data is crucial, balancing safety and effectiveness with innovation and research, while ensuring industry access to anonymized data

Elena Popova emphasized the interdisciplinary nature of modern technologies and the necessity for close collaboration between science, industry, and regulators.